Every material Form 8-K CITY THERAPEUTICS, INC. has filed with the SEC since November 10, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
City Therapeutics announced that the first participant has been dosed in a Phase 1 clinical trial of CITY-RBP4, an investigational RNAi therapeutic for Stargardt disease. The company expects to report initial data from the trial in mid-2027, and the filing contains no financial results, guidance or deal terms.
First participant dosed in Phase 1 trial of CITY-RBP4 for Stargardt disease type 1, announced November 10, 2026
City expects to report initial Phase 1 data in mid-2027
CITY-RBP4 is City's second program to enter the clinic; a third program is expected to enter the clinic through an investigator-initiated trial by year-end
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CITY THERAPEUTICS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →